Palvella Therapeutics (PVLA) Invested Capital: 2013-2024
Historic Invested Capital for Palvella Therapeutics (PVLA) over the last 11 years, with Sep 2024 value amounting to -$87.4 million.
- Palvella Therapeutics' Invested Capital fell 386.48% to -$87.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$87.4 million, marking a year-over-year decrease of 386.48%. This contributed to the annual value of -$74.5 million for FY2023, which is 366.69% down from last year.
- Latest data reveals that Palvella Therapeutics reported Invested Capital of -$87.4 million as of Q3 2024, which was down 8.14% from -$80.8 million recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Invested Capital registered a high of $53.9 million during Q3 2021, and its lowest value of -$87.4 million during Q3 2024.
- Over the past 3 years, Palvella Therapeutics' median Invested Capital value was $27.9 million (recorded in 2022), while the average stood at -$6.5 million.
- Its Invested Capital has fluctuated over the past 5 years, first surged by 139.53% in 2020, then crashed by 597.30% in 2024.
- Quarterly analysis of 5 years shows Palvella Therapeutics' Invested Capital stood at $31.0 million in 2020, then soared by 63.58% to $50.8 million in 2021, then tumbled by 44.97% to $27.9 million in 2022, then slumped by 366.69% to -$74.5 million in 2023, then tumbled by 386.48% to -$87.4 million in 2024.
- Its Invested Capital was -$87.4 million in Q3 2024, compared to -$80.8 million in Q2 2024 and -$76.9 million in Q1 2024.